Company Overview and News

40
W.W. Grainger: Zig When Others Zag

2018-10-17 seekingalpha
The investment community did not react well to GWW’s Q3 2018 results which were released October 16th.
AMZN GWW MSM WCC FAST HDS AIT AXE

1
AIT / Applied Industrial Technologies, Inc. / VANGUARD GROUP INC - null (Passive Investment)

2018-10-10 sec.gov
appliedindustrialtechnologie.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
AIT

1
AIT / Applied Industrial Technologies, Inc. / VANGUARD GROUP INC - null (Passive Investment)

2018-10-10 sec.gov
appliedindustrialtechnologie.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
AIT

1
Monmouth Real Estate Investment upgraded to buy from neutral at B. Riley FBR

2018-10-09 marketwatch
Boenning & Scattergood analyst Merrill Ross maintained a Buy rating on Monmouth Real Estate ate ...[...]
TFSL MNR AIT GPMT

1
AIT / Applied Industrial Technologies, Inc. DEF 14A

2018-09-14 sec.gov
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION W
AIT

1
Applied Industrial Technologies Recognized as a Best Workplace for Top Talent

2018-09-13 globenewswire
CLEVELAND, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Applied Industrial Technologies (NYSE: AIT) has received the annual NorthCoast 99 Award for 2018, honoring companies that are the best workplaces in Northeast Ohio based on their ability to attract, retain and motivate top-performing employees. This is the 18th year Applied® has received this prestigious award.
AIT

1
Applied Industrial Technologies: Further Growth Ahead

2018-08-23 seekingalpha
AIT has accelerated growth over recent quarters, beating the market consensus earnings consistently over the last 12 months.
AIT

1
AIT / Applied Industrial Technologies, Inc. 10-K (Annual Report)

2018-08-17 sec.gov
Document Table of Contents
AIT

7
Molina Healthcare (MOH) Soars to a 52-Week High, Time to Cash Out?

2018-08-14 zacks
Have you been paying attention to shares of Molina Healthcare (MOH - Free Report) ? Shares have been on the move with the stock up 24.6% over the past month. MOH hit a new 52-week high of $133.29 in the previous session. Molina Healthcare has gained 72.2% since the start of the year compared to the 4.1% move for the Medical sector and the 19.1% year-to-date return for its peer group.
MOH AIT URBN

12
Urban Outfitters (URBN) Hits a 52-Week High, Can the Run Continue?

2018-08-14 zacks
Have you been paying attention to shares of Urban Outfitters (URBN - Free Report) ? Shares have been on the move with the stock up 6.6% over the past month. URBN hit a new 52-week high of $49 in the previous session. Urban Outfitters has gained 35.2% since the start of the year compared to the 14.9% move for the Retail-Wholesale sector and the 3.7% year-to-date return for its peer group.
MOH BKE AIT FL URBN

1
ABB Poised on Solid Traction Across Markets, Risks Remain

2018-08-14 zacks
On Aug 14, we issued an updated research report on ABB Ltd (ABB - Free Report) .
ABB AIMC ABLZF AIT

1
Crown Holdings (CCK) Rides on Acquisitions Amid Rising Costs

2018-08-14 zacks
On Aug 13, we issued an updated research report on Crown Holdings, Inc. (CCK - Free Report) . The company is poised to gain from geographic expansion, acquisitions and focus on capital allocation. Its Transit Packaging business also remains a growth driver. Nevertheless, elevated freight costs, foreign currency-translation impact and raw-material inflation might impede the company’s near-term growth.
ROP STQN CCK AIT GTLS

2
Here's Why You Should Buy Applied Industrial (AIT) Stock Now

2018-08-14 zacks
The U.S. GDP growth tapped the best gain in the past four years during the April-June quarter. Solid business and consumer spending, along with growth in exports, helped drive economic growth in the country.
[DXPE] DXPE AIMC CFX AIT

4
Here's Why You Should Add DXP Enterprise to Your Portfolio

2018-08-13 zacks
DXP Enterprises, Inc. (DXPE - Free Report) has impressed investors with its recent earnings results, wherein the top line and bottom line surpassed the Zacks Consensus Estimate. We believe that strong traction across the company’s operational segments and accretive acquisitions might continue to be growth drivers, going ahead.
[DXPE] ROLL FOX DXPE AIMC AIT LMHA LMHB FOXA LM

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to AIT / Applied Industrial Technologies, Inc. on message board site Silicon Investor.

Waiting for the big Kahuna Waiting for the big Kahuna Waiting for the big Kahuna Nigerian Scam Baiting - Letu0027s Discuss the Modalities Nigerian Scam Baiting - Letu0027s Discuss the Modalities Nigerian Scam Baiting - Letu0027s Discuss the Modalities
Texas Instruments - Good buy now or should we wait? Texas Instruments - Good buy now or should we wait? Texas Instruments - Good buy now or should we wait? ETRM----If You Have the Weight ,Then You Canu0027t Wait for ETRM ETRM----If You Have the Weight ,Then You Canu0027t Wait for ETRM ETRM----If You Have the Weight ,Then You Canu0027t Wait for ETRM
Intellipharma (IPCI) MC $44 M // 8 Drugs awaiting FDA appro Intellipharma (IPCI) MC $44 M // 8 Drugs awaiting FDA appro Intellipharma (IPCI) MC $44 M // 8 Drugs awaiting FDA appro IPCI (MC $63 M ) 7 Drugs awaiting FDA approval /Low Float IPCI (MC $63 M ) 7 Drugs awaiting FDA approval /Low Float IPCI (MC $63 M ) 7 Drugs awaiting FDA approval /Low Float
Waiting for Goldot Waiting for Goldot Waiting for Goldot Edward Snowden: Traitor, or National Hero? Edward Snowden: Traitor, or National Hero? Edward Snowden: Traitor, or National Hero?
Cadre Resources (CSL.V) Awaiting production #u0027s and Financ Cadre Resources (CSL.V) Awaiting production #u0027s and Financ Cadre Resources (CSL.V) Awaiting production #u0027s and Financ 6 Drugs awaiting FDA approval (Mcap 47 M) 6 Drugs awaiting FDA approval (Mcap 47 M) 6 Drugs awaiting FDA approval (Mcap 47 M)
CUSIP: 03820C105